About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin businesses feel the strain despite a strong dollar.

Veru Inc (NASDAQ:VERU) reported positive top-line results from its Phase 2B clinical study for Novosarm, showing significant preservation of lean body mass in older patients. The company ...

VERU has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Veru in a research note on Thursday, January 2nd ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation, pharmacokinetic ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...